|

Presentations

Saturday, 21 September
Welcome and Introductions
Opening Remarks
Peter Hillmen		 view_pres-01
History of CLL
Gerald Marti		 view_pres-01
Session 1:
 The CLL (Epi)genome
Chair(s): Christopher Oakes, and Tatjana Stankovic
Overview of the CLL Genome
Jonathan Strefford		 view_pres-01
The Epigenetic Features of CLL:
DNA Methylation
Christoph Plass		 view_pres-01
Insights From Tertiary Structure, Chromatin
Modifications, and Nuclear Organization
José Ignacio Martín-Subero		 view_pres-01
*Comprehensive genomic testing for chronic lymphocytic leukaemia patients: WGS, one key to patient stratification (2086)
Kate Ridout		 view_pres-01
*BIRC3 loss accelerates leukemic progression through activation of the non-canonical NF-kB signaling of del(11q) CLL cells (2133)
Miguel Quijada-Álamo		 view_pres-01
**Leukemia specific delivery of miR29b induces epigenetic reprogramming with cell cycle arrest and therapeutic benefit in Chronic Lymphocytic Leukemia (2188)
Natarajan Muthusamy		 view_pres-01
**Cooperation between SF3B1 mutation and ATM deletion in the development of CLL (2194)
Lili Wang		 view_pres-01
Session 2:
 The CLL (Epi)genome (cont.)
Chair(s): Sarka Pospisilova, and Deepa Sampath
Keynote
Evolution and Mathematical Modelling of
Cancer Genomes
Gad Getz		 Presentation
Not Available
Functional Implications of Genomic Lesions
Catherine Wu		 view_pres-01
The Impact of Regulatory RNA Molecules
Marek Mráz		 view_pres-01
ATM: Pathway, Lesions, and Targeting
Tatjana Stankovic		 view_pres-01
*Effect of second-generation BTK inhibitors on the functionality of macrophages and neutrophils from CLL patients. (2088)
Mercedes Borge		 view_pres-01
*Pyroptosis as a drugable cell death pathway in Chronic Lymphocytic Leukemia: The other side of inflammation. (2052)
Pablo Oppezzo		 view_pres-01
**Clinical impact of clonal and subclonal TP53 mutations and deletions in chronic lymphocytic leukemia: an Italian multicenter experience (2130)
Riccardo Bomben		 view_pres-01
**Minor-clone TP53 mutations in CLL patients entering first-line treatment: clonal evolution and clinical impact (2136)
Jitka Malcikova		 view_pres-01
Session 3: The B-Cell Receptor
Chair(s): Andrew Steele, and Jan Burger
Role of the B-Cell Receptor in B-Cell
Oncogenesis
Stefano Casola		 view_pres-01
Dissecting CLL Immunogenetics and
Emerging B-Cell Receptor Stereotypes
Kostas Stamatopoulos		 view_pres-01
CLL-Specific Aspects of B-Cell Receptor
Signaling
Graham Packham		 view_pres-01
*Using signal-omics to fingerprint the impact of antigen engagement and therapy on BCR activation in CLL. (1904)
Adam Linley		 view_pres-01
*Functional interplay between the B-cell receptor and NOTCH1 in Chronic Lymphocytic Leukemia and in Richter’s syndrome (2065)
Francesca Arruga		 view_pres-01
**Targeting MDSCs in CLL-bearing mice by suppressing the synthesis of secretory IgM via activation of RIDD (1987)
Chih-Chi Hu		 view_pres-01
**Ibrutinib therapy downregulates AID enzyme and proliferative fractions in chronic lymphocytic leukemia (2047)
Pablo Morande		 view_pres-01
**Distinct Immune Signatures in Chronic Lymphocytic Leukemia and Richter Syndrome (2062)
Yucai Wang		 view_pres-01
Session 4: Microenvironment and Models of CLL
Chair(s): Christopther Pepper, and Varsha Gandhi
Linking the Microenvironment With CLL
Models
Nicholas Chiorazzi		 view_pres-01
In Vitro Modelling of the CLL
Microenvironment
Alan Ramsay		 view_pres-01
Murine and Xenograft Models of CLL
Shih-Shih Chen		 view_pres-01
Role of NOTCH1 in CLL and in Richter’s Transformation
Silvia Deaglio		 view_pres-01
*Mechanisms of Ibrutinib resistance in the Eµ-TCL-1 mouse model of chronic lymphocytic leukemia (2124)
Martina Seiffert		 view_pres-01
*3D-culture of CLL cells in bioreactor identifies the bone marrow as a key regulator of HS1 function in response to Ibrutinib (1932)
Cristina Scielzo		 Presentation
Not Available
**Analyzing the mutational landscape of two CLL mouse models overexpressing AID identifies proliferative fraction-associated tumor genes involved in leukemic development and progression (2049)
Pablo Morande		 view_pres-01
**Modelling Chronic Lymphocytic Leukemia microenvironment in vitro by exploiting newly-established 3D systems (2006)
Francesca Vittoria Sbrana		 view_pres-01
**Chronic lymphocytic leukemia remodels the fibroblastic reticular network that contributes to immunosuppression in the tumor microenvironment (2166)
Natalia Couto-Francisco		 Presentation
Not Available
**IL10-producing CD38hi B-regulatory cells drive the immunosuppressive microenvironment in CLL and can be targeted with anti-CD38 immunotherapy (2193)
Alak Manna		 Presentation
Not Available
Sunday, 22 September
Session 5: Innovations in the Assessment of CLL
Chair(s): Alessandra Ferrajoli, and Nicole Lamanna
Laboratory Assessment of CLL, Including MRD
as an End Point
Andrew Rawstron		 view_pres-01
Molecular Characterization of CLL
Richard Rosenquist Brandell		 Presentation
Not Available
Clinical Assessment of CLL
Carol Moreno		 view_pres-01
Critical Assessment and New Development of
Prognostic Scoring Systems
Barbara Eichhorst		 view_pres-01
*Gene expression signatures predict time-to-progression after front-line chemoimmunotherapy for CLL (1925)
Kevin Coombes		 view_pres-01
*Ibrutinib versus placebo in patients with asymptomatic, treatment-naïve early stage chronic lymphocytic leukemia (CLL): primary endpoint results of the phase 3 double-blind randomized CLL12 trial. (1938)
Petra Langerbeins		 view_pres-01
**Undetectable minimal residual disease should be the goal of venetoclax therapy in relapsed and refractory chronic lymphocytic leukaemia (2089)
Thomas Lew		 view_pres-01
**Predicting tumor lysis syndrome in venetoclax-treated CLL patients (2008)
Anthony Mato		 view_pres-01
Session 6:
 Initial Therapy
Chair(s): Steven Coutre, and Adrian Bloor
Early Intervention: Can We Justify It and What
End Points Should We Consider?
Petra Langerbeins		 view_pres-01
Current Initial Treatment of CLL – for Young
Patients
Florence Cymbalista		 view_pres-01
Current Initial Treatment of CLL – for Elderly
Patients
Valentin Goede		 view_pres-01
Treatment of CLL from 2019 Onwards: E1912 Trial
Tait Shanafelt		 Presentation
Not Available
Treatment of CLL from 2019 Onwards: Alliance Trial
Danielle Brander		 view_pres-01
Treatment of CLL from 2019 Onwards: iLLUMINATE Trial
Alessandra Tedeschi		 view_pres-01
Treatment of CLL from 2019 Onwards: CLL14 Trial
Kirsten Fischer		 view_pres-01
*Ibrutinib for first-line treatment of chronic lymphocytic leukemia in patients aged ≥65 year of age: results with 5 years of follow-up for the RESONATE-2 study (1956)
Alessandra Tedeschi		 view_pres-01
*Obinutuzumab and ibrutinib treatment induction followed by a minimal residual disease-driven strategy in chronic lymphocytic leukaemia: long-term results in the ICLL-07 FILO trial (1962)
Anne-Sophie Michallet		 Presentation
Not Available
**Obinutuzumab as consolidation after chemo-immunotherapy is highly effective in achieving MRD clearance from bone marrow and peripheral blood resulting in improved Progression-free survival: Results of UK NCRI Phase II/III GALACTIC trial (2121)
Talha Munir		 view_pres-01
**Long-term efficacy and safety of maintenance with lenalidomide in patients with chronic lymphocytic leukaemia and a high risk of progression after first-line immunochemotherapy (2017)
Moritz Fürstenau		 view_pres-01
Keynote
Overview of Clonal Evolution and Genomic Instability in CLL and Implications for Therapy
Daniel Landau		 Presentation
Not Available
Session 7:
 Resistance Mechanisms
Chair(s): Bryone Kuss, and Loic Ysebaert
Development of Resistance to B-Cell Receptor
Inhibition
Jennifer Woyach		 Presentation
Not Available
Development of Resistance to BCL2 Inhibition
Mary Ann Anderson		 view_pres-01
*Prevalence of BTK and PLCG2 mutations in chronic lymphocytic leukemia patients relapsing on ibrutinib: a European Research Initiative on CLL (ERIC) real-world study (2098)
Lesley-Ann Sutton		 Presentation
Not Available
*High surface tumor IgM levels associate with reduced response duration and with BTK bypass during ibrutinib therapy in CLL patients (2195)
Giorgia Chiodin		 Presentation
Not Available
**CD8+ T-cell exhaustion induced by leukemic cells mediates progression in Chronic Lymphocytic Leukemia (CLL) (2096)
Isabel Jiménez		 view_pres-01
Binet/Rai Medal Presentation Presentation
Not Available
Monday, 23 September
Session 8:
 Therapy of Relapsed/Refractory CLL
Chair(s): Jacqueline Barrientos, and Barbara Eichhorst
B-Cell Receptor-Inhibitor Therapy in Relapsed/
Refractory Disease
Susan O’Brien		 view_pres-01
BCL2-Inhibitor-Based Therapy and MRD in
Relapsed/Refractory Disease
John Seymour		 view_pres-01
Novel Combinations and MRD in Relapsed/
Refractory Disease
Matthew Davids		 view_pres-01
Defining Duration of Therapy: Is There a Role
for MRD?
Talha Munir		 view_pres-01
*Venetoclax combined with ibrutinib based on a minimal residual disease-guided approach in relapsed/refractory chronic lymphocytic leukemia: results of the IMPROVE study (2068)
Lydia Scarfo		 Presentation
Not Available
*Ibrutinib plus venetoclax in Relapsed/Refractory CLL: The CLARITY Study (2143)
Talha Munir		 view_pres-01
**Biological responses to ibrutinib plus venetoclax in the Bloodwise TAP CLARITYstudy (2163)
Andrew Rawstron		 view_pres-01
**Pneumocystis jirovecii pneumonia and invasive fungal infection incidence and institutional prophylaxis practices in CLL patients treated with BTK inhibitors (1941)
Christine Ryan		 view_pres-01
Session 9:
 Novel Strategies in Rel/Refr CLL
Chair(s): George Follows, and Adrian Wiestner
Evolution of Small Molecule Inhibitors:
New vs Old
John Byrd		 Presentation
Not Available
Updates on Immune Therapy Strategies,
Including CAR T-Cell Therapy and Stem Cell
Transplant
Katy Rezvani		 view_pres-01
*ASCEND Phase 3 study of acalabrutinib vs investigator’s choice of rituximab plus idelalisib (IdR) or bendamustine (BR) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) (2158)
Wojciech Jurczak		 view_pres-01
*T cell bispecific antibody combination immunotherapy for chronic lymphocytic leukemia (2063)
Despoina Papazoglou		 Presentation
Not Available
**A Phase 2 Study to Assess the Safety and Efficacy of Umbralisib in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K Delta Inhibitor Therapy (1943)
Danielle Brander		 view_pres-01
**Biology and targeting of mutant p53 in CLL (2172)
Janani Ravikrishnan		 view_pres-01
Debate: Future Management of CLL:
Is There a Role for Cellular Therapy?
Moderator: Anna Schuh
David Maloney (CAR T)
Johannes Schetelig (SCT)
Matt Davids (Novel-Novel)		 view_pres-01
Session 10:
 Real-World Data and Registries
Chair(s): Neil Kay, and Eva Kimby
CLL Clinical Genomics: Overview of the
National Programmes in Sweden, the US, the
UK, and France
Anna Schuh		 view_pres-01
Geographic Diversity and Management of CLL
in South American Patients
Carlos Sérgio Chiattone		 Presentation
Not Available
Geographic Diversity and Management of CLL
in African Patients
Norah Akinola		 view_pres-01
Geographic Diversity and Management of CLL
in Indian Patients
Abraham Varghese		 view_pres-01
Geographic Diversity and Management of CLL
in Chinese Patients
Shenmiao Yang		 view_pres-01
Session 11:
 iwCLL UPDATES
Chair: Peter Hillmen
Reorganization of the iwCLL
Michael Hallek		 view_pres-01
An Update From the European Research
Initiative on CLL (ERIC)
Paolo Ghia		 view_pres-01
Current Efforts From European and US
Real-World Data
Christopher Fox (EU) and Anthony Mato (US)		 Presentation
Not Available
Closing Comments
Peter Hillmen		 view_pres-01